Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Immuno-inflammatory profile description in patients with ischemic stroke.
- Who it may be relevant to
- Registry conditions: Stroke, Ischemic Stroke. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies
Overview
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.
Interventions
- Other Immuno-inflammatory profile description in patients with ischemic stroke
Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
Primary outcome measures
- Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment [Time frame: Up to year]
Eligibility criteria
Inclusion criteria
- Patient over 18 years of age
- Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)
- Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)
- Affiliated with or beneficiary of a social security system
Exclusion criteria
- Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)
- Intracranial hemorrhage associated with AIC on initial imaging
Immunosuppressive treatment or corticosteroid therapy at patient admission
- Pre-existing neurological disability limiting neurological assessment at 3 months (mRS>2 at admission)
- Known and diagnosed dementia pre-existing at the time of the AIC
- Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance <15mL/min, pregnant or breastfeeding women)
- Patient treated by another institution and referred solely for mechanical thrombectomy
- Patient benefiting from legal protection measures
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT04701619 · BMR_2020_31